<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-049335</identifier>
<setSpec>0365-6691</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Side-effects of triamcinolone in young patients</dc:title>
<dc:description xml:lang="en">Case reports: Intravitreal triamcinolone is being ;;increasingly employed for the treatment of macular ;;diseases. We report two cases of intraocular pressure ;;elevation and cataract formation after intravitreal ;;triamcinolone therapy, and wonder if these complications ;;are more likely when this agent is used in ;;young patients. ;;Intravitreal triamcinolone was injected into both ;;eyes of the two young patients with chronic posterior ;;and intermediate uveitis refractory to peribulbar ;;and oral corticosteroid therapy. Chronic cystoid ;;macular edema improved in both patients, however ;;the intraocular pressure increased, requiring topical ;;antihypertensive therapy, and this was followed by ;;accelerated cataract formation. ;;Discussion: Young age and chronic inflammation ;;could be associated with an intraocular pressure rise ;;and subsequent cataract development after intravitreal ;;triamcinolone</dc:description>
<dc:creator>Suárez-Figueroa, M</dc:creator>
<dc:creator>Noval, S</dc:creator>
<dc:creator>Contreras, I</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Casos clínicos: El uso de triamcinolona intravítreaestá extendiéndose como tratamiento de enfermedadesmaculares. Los efectos secundarios puedenvariar en jóvenes. Presentamos dos casos de incrementode la presión intraocular (PIO) y desarrollode cataratas. Dos pacientes jóvenes con uveítis crónicasrefractarias a glucocorticoides perioculares yorales, recibieron inyecciones intravítreas de triamcinolona.El edema macular crónico mejoró en ambos pacientes.Se produjo un incremento de PIO, seguido de laaparición acelerada de cataratas.Discusión: La juventud y la inflamación crónicapodrían estar asociadas a incrementos de PIO y elconsecuente desarrollo de cataratas tras inyecciónintravítrea de triamcinolona</dc:description>
<dc:source>Arch Soc Esp Oftalmol;81(7): 405-408, jul. 2006. ilus</dc:source>
<dc:identifier>ibc-049335</dc:identifier>
<dc:title xml:lang="es">Efectos secundarios de la triamcinolona en pacientes jóvenes</dc:title>
<dc:subject>^d15007^s22057</dc:subject>
<dc:subject>^d29315</dc:subject>
<dc:subject>^d19035^s22036</dc:subject>
<dc:subject>^d28204^s22036</dc:subject>
<dc:subject>^d22707^s22020</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d906^s22020</dc:subject>
<dc:type>article</dc:type>
<dc:date>200607</dc:date>
</metadata>
</record>
</ibecs-document>
